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Abstract
Objective: Heparin-induced thrombocytopenia (HIT) is a life threatening complication of heparin therapy, causing 
thrombosis. The aim of our study was to find out the frequencies of HIT antibody seroconversion and clinical HIT in Turkish 
medical patients on different forms of heparins. 
Materials and Methods: Our study included 61 patients who were on unfractionated heparin (UFH) (n: 37) and low 
molecular weight heparin (LMWH) (n: 24) therapies. The frequency of HIT antibody formation was determined by means 
of antigenic (ELISA), and functional assays (serotonin release assay-SRA). 
Results: The seroconversion rates in UFH and LMWH groups were found to be 18.9% and 4.1% (ELISA), and 8.1% and 
4.1% (SRA), respectively. One patient (2.1%) on UFH therapy developed deep vein thrombosis. No thromboembolic event 
was observed in patients taking LMWH. 
Conclusion: Seroconversion rates by means of antigenic and functional assays and clinical HIT were more common in 
patients on UFH than patients on LMWH therapy. (Turk J Hematol 2009; 26: 171-5)
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Özet
Amaç: Heparine bağlı trombositopeni (HİT) heparin tedavisinin tromboza neden olan, hayatı tehdit eden bir komplikasyo-
nudur. Çalışmamızın amacı farklı heparin formları kullanan dahili Türk hastalarda HİT antikor serokonversiyonu ve klinik HİT 
sıklığının saptanmasıydı. 
Yöntem ve Gereçler: Çalışmamıza anfraksiyone heparin (AFH) (n: 37) ve düşük molekül ağırlıklı heparin (DMAH) (n: 24) 
tedavisi alan 61 hasta katıldı. HIT antikor oluşumu antijenik (ELISA) ve fonksiyonel (serotonin salınım testi-SRA) testler ile 
değerlendirildi.Introduction
Heparin is an important anticoagulant drug which is widely 
used in almost every discipline of medicine and has saved 
thousands of lives for over 50 years. The most feared 
complications of heparin therapy are hemorrhage and heparin-
induced thrombocytopenia (HIT). HIT is an acquired, transient, 
prothrombotic disorder and a life-threatening complication of 
unfractionated (UFH) and low molecular weight heparin   
(LMWH)  therapy presenting with thrombocytopenia and/or 
complicating venous or arterial thromboembolism that is 
associated with increased in vivo thrombin generation [1]. HIT 
is a clinicopathologic condition and adverse drug reaction 
caused by platelet-activating antibodies of mostly pathogenic 
IgG class which are directed against a molecular complex 
formed by heparin and platelet α-granule protein, platelet 
factor 4 (PF4) [2]. The frequency of HIT is dependent on four 
factors: duration of heparin use (>1 week versus<1 day), type 
of heparin (UFH>LMWH>fondaparinux which is synthetic 
heparin pentasaccharides), type of patient population (surgery> 
medical>pregnancy), and patient gender (female>male) [3]. HIT 
occurs in 3% to 5% and 0.5% of patients receiving UFH and 
LMWH, respectively [4]. In the absence of alternative 
anticoagulation, the risk of thrombosis is ~ 5% to 10% per day 
in the first few days after cessation of heparin [5] and mortality 
from HIT ranges from 18-50% [6]. In medical conditions, the 
frequency of both antibody formation and thrombocytopenia 
or/and thrombosis are much less than in surgical settings [7,8]. 
The confirmation of HIT by laboratory methods is complex and 
difficult but is a sine qua non of HIT diagnosis. To date, there 
are two types of assays used to measure the antibody 
formation (immunologic and functional assays) [9-11]. The 
frequency of AHPF4 formation is much greater than the risk of 
HIT and only minority of antibodies detected with EIA are able 
to activate platelets in vivo. The interrelationship between 
antibody formation and clinical HIT has been demonstrated 
with an iceberg model [11]. We recently reported the frequency 
of AHPF4 antibody formation and clinical HIT in Turkish 
patients undergoing cardiac surgery [12]. Our study was 
designed to establish the laboratory methods of HIT and to 
determine the frequency of antibody generation and clinical 
HIT events in medical patients in Turkey. 
Materials and Methods 
Patients Selection: This prospective study enrolled a total 
of 61 consecutive medical patients who were treated at a 
single institution (Trakya University Hospital) during 2004-2005 
and no history of recent (< 100 days) heparin/LMWH exposure. 
37 patients with acute coronary syndrome (ACS) and venous 
thromboembolism (VTE) (deep vein thrombosis (DVT) and/or 
pulmonary embolism (PE)) who were treated with UFH for at 
least 5±2 days, and 24 DVT patients who were on therapeutic 
dose LMWH therapy for at least 6±2 days were included. 
Patients of LMWH therapy arm were treated with nadroparin 
(n=5), dalteparin (n=5), and enoxaparin (n=14). Written informed 
consent was obtained from all patients. The study was 
conducted according to the Declaration of Helsinki. 
Sample collections: Blood samples were taken on 10±2. 
days of heparin therapy. Daily and alternate day platelet counts 
were performed on patients belonging to UFH and LMWH 
therapy arm, respectively. Thromboembolic attacks were 
evaluated on clinical grounds. In suspected cases radiological 
(Doppler ultrasonography and/or spiral computerized 
tomography), and scintigraphic (ventilation-perfusion scan) 
confirmations were made. The first day of heparin exposure 
was considered day 0. Ten ml of blood without anticoagulant 
was taken and allowed to incubate at room temperature for 1 
hour to assure blood clot formation. The samples were 
centrifuged at 3000/min for 15 minutes. All serum samples 
were inactivated by heat inactivation at 56 ºC for 45 minutes 
and stored at -85 ºC until tested. 
Laboratory assays: For determining the antibodies, both 
antigenic and activation assays were carried out. The 
determination of anti-heparin/platelet factor 4 antibodies 
(HPF4-A) was performed as previously described by using a 
commercially available ELISA kit (Asserachrome HPIA; 
Diagnostica Stago, France) [11]. The positive results were 
defined as an absorbance value of equal or greater than 0.5 
optical density units at A492 nm. This ELISA kit detected two 
other anti-human immunoglobulin (Ig) classes (Ig A and Ig M) 
besides Ig G. 
Heparin-PF4 dependent platelet reactive antibodies were 
detected with two functional assays, the platelet aggregation 
test (PAT) and the serotonin release assay (SRA). The patient 
samples were tested in duplicate with different platelet donors. 
A pool of ten normal-healthy-previously tested donors’ platelets 
were used in these activation assays. PAT was performed as 
previously reported [9,13]. In this method, platelet rich citrated 
plasma was used and the samples were considered positive if 
≥20% maximum aggregation was met at 0.1 to 1.0 U/ml 
heparin concentrations. Aggregation response was monitored 
for 20 min. SRA was performed as previously described [9,14]. 
For the SRA, the samples were considered positive if all the 
following criteria were met: 1) ≥20% serotonin release at 0.1U/
ml heparin and 2) inhibition of platelet activation at high 
concentration of heparin (100 U/ml) 3) appropriate activation 
profiles observed with positive and negative control samples. If 
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Bulgular: AFH ve DMAH gruplarında serokonversiyon oranları sırasıyla %18,9-%4,1 (ELISA) ve %8,1-%4,1 (SRA) saptandı. 
AFH kullanan bir hastada (%2,1) derin ven trombozu gelişti. DMh kullanan hastalarda tromboembolik olay izlenmedi. 
Sonuç: aFH kullanan hastalarda dmah kullananlara göre antijenik ve fonksiyonel yöntemlerle serokonversiyon ve klinik HIT 
oranları daha yüksek saptandı. (Turk J Hematol 2009; 26: 171-5)
Anahtar kelimeler: Heparine bağlı trombositopeni, medikal hastalar, Türk hasta grubu, fraksiyone olmayan heparin, 
düşük molekül ağırlıklı heparin
Geliş tarihi: 28 Mayıs 2009  Kabul tarihi: 29 Eylül 2009a patient sample was negative by PAT or SRA, it was repeated 
in duplicate with a different platelet donor.
Definition of HIT: HIT was defined according to the 
following criteria. 1) unexplained absolute or relative 
thrombocytopenia with a decrease of 50% from baseline 
platelet counts after day 5 of heparin therapy for no other 
reason except heparin treatment. 2) new thromboembolic 
complications such as venous or arterial thrombosis associated 
with heparin exposure and not due to surgery, thrombophilia, 
DIC, etc. 3) laboratory evidence of anti-heparin-platelet factor 
4 antibodies. 
Statistical analysis: All statistical calculations were 
performed by using Microsoft Excel software. Results were 
expressed as mean ± standard deviation. The positive results 
were given as percent value of total patient number. Chi-
square test was used to compare seroconversion rates among 
groups. The p value if equal or lower than 0.05 was considered 
as significant. 
Results 
The study cohort included 37 patients (11 female, 26 male) 
with acute coronary syndrome (n:29) and VTE (n:8) (DVT and/
or PE), and 24 DVT patients ( 12 female, 12 male). Mean age 
of patients on UFH and LMWH therapy were 65±9.5 years and 
61±7.2 years, respectively. The frequency of HIT antibody 
generation measured by ELISA in patients taking UFH and 
LMWH were found to be 18.9% and 4.1%, respectively. SRA 
detected HIT antibodies in 8.1% of patients on UFH and 4.1% 
of patients on LMWH therapy. PAT was positive in 8 patients 
(21.6%) on UFH and 1 (4.1%) patient on LMWH therapy. One 
patient (2.1%) with ACS who was on UFH therapy developed 
DVT. No thromboembolic attack was observed in patients 
taking LMWH (Figure 1 and 2). Seroconversion rates by means 
of ELISA (p: 0.01), PAT (p: 0.02) and SRA (p: 0.04) and clinical 
HIT were more common in patients on UFH than patients on 
LMWH therapy (Figure 3). 
Discussion
HIT is a very strong risk factor for arterial and venous 
thromboembolism, both in relative (odds ratio for thrombosis = 
20-40) and absolute (thrombosis risk 30-45%) terms, 
depending on the patient population affected [15]. As HIT is a 
clinicopathologic syndrome its diagnosis depends on any 
clinical event related to heparin exposure like thrombocytopenia, 
thrombosis, anaphlaxis and demonstration of HIT antibody 
serocoversion by serologic and functional assays. Only a 
minority of patients with antibody seroconversion develops 
HIT. In one third to one half of the cases isolated HIT-defined 
as HIT presented with thrombocytopenia but without 
thrombosis- is subsequently complicated by thrombosis [16]. 
Therefore simply discontinuing heparin is not enough to 
prevent thromboembolic complications and an alternative 
nonheparin anticoagulant should be commenced immediately 
in case of highly probable or confirmed HIT. In order to prevent 
HIT overdiagnosis a clinical scoring system (4Ts) is very useful 
for predicting pretest probability of HIT [17].
In general both seroconversion, thrombocytopenia and 
thrombosis rates are lower among medical patients compared 
to surgical patients. Because we did not perform baseline 
search for HIT antibodies, we cannot exclude that some 
patients were already seropositive before study entry. In three 
different reports on ACS patients who were treated with UFH 
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HITT
(2.1%)
Platelet activating antibody formation
SRA (8.1%)
PAT (21.6%)
Seroconversion rate by means of ELISA
(18.9%)
No measurable antibodies against heparin
(81%)
Figure 1. Data on the frequency of antibody generation and clinical HIT in medical patients on UFH therapy are presented as an iceberg model. SRA: 
Serotonin release assay; PAT: Platelet aggregation assay; HITT: Heparin induced thrombocytopenia thrombosisseroconversion rates were found to be 8.7%, 10.6% and 30%, 
respectively [11,18,19]. There is a trend for increased 
seropositivity with time both in surgical and medical patients on 
heparin and LMWH therapy [12,20]. In their multicenter study 
Lindhoff-Last E et al. [20] evaluated a total of 1137 patients 
with DVT who were randomly assigned to UFH or reviparin for 
5-7 days. On day 5-7 the incidence of AHPF4 were found to 
be 9.1% and 3.7%, who were on UFH and LMWH therapy, 
respectively. These values were 20.7% (UFH) and 7.5% 
(LMWH) on day 21. In our study seroconversion rates were 
18.9% and 4.1% for patients on UFH and LMWH, respectively. 
As we did not perform serologic assays on different time 
periods we were not able to demonstrate this phenomenon. Ig 
A and IgM antibodies cannot activate platelets by way of Fcγ 
(IgG) receptors and therefore not pathogenic. As our ELISA kit 
detected both IgA and IgM antibodies besides IgG, our results 
could be an overestimation of true seroconversion rates. The 
incidence of HIT associated thrombosis among medical 
patients varies between 0.8%-1.6% and 0.53%-0.8% in 
Demir et al.
HIT in medical patients  Turk J Hematol 2009; 26: 171-5 174
HITT
(0%)
Platelet activating antibody formation
SRA (4.1%)
PAT (4.1%)
Seroconversion rate by means of ELISA
(4.1%)
No measurable antibodies against heparin
(95.9%)
Figure 2. Data on the frequency of antibody generation and clinical HIT in medical patients on LMWH therapy are presented as an iceberg 
model. SRA: Serotonin release assay; PAT: Platelet aggregation assay; HITT: Heparin induced thrombocytopenia thrombosis
Results of both antigenic and activation assays 
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Figure 3. Results of serologic and functional assays on heparin and 
LMWH
Table 1. The clinical and laboratory results of SRA positive samples
Age /Sex  Heparin  ELISA  SRA  Platelet count  Minimum platelet  Thromboembolic 
  type  (OD)  (% release)  at study entry  count during  event
       (mm3)   study period (mm3)
77/F UFH  0,870  74  222000  192000  -
75/M UFH  2,870  85  267000  212000  DVT
66/M UFH  0,807  65  288000  292000  -
62/F LMWH  0,555  59  198000  188000  -
F: Female; M: Male; OD: Optical density; SRA: Serotonin release assay; DVT: Deep vein thrombosispatients on UFH and LMWH treatment, respectively [7,8,18,20]. 
Seroconversion rates by means of antigenic and functional 
assays and clinical thrombosis on our patient cohort are 
compatible with the vast majority of reports on HIT in the 
literature. 
In conclusion, seroconversion rates and clinical HIT were 
more common in patients on UFH than patients on LMWH 
therapy. The small patient number, the most important 
shortcoming of our study, make it difficult to draw any firm 
conclusions. Nevertheless, as far as we know this is the first 
effort evaluating the frequency of HIT among Turkish medical 
patients on different heparin preparations.
No author of this paper has a conflict of interest, including 
specific financial interests, relationships, and/or affiliations 
relevant to the subject matter or materials included in this 
manuscript.
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